MagForce AG Installs Fifth Nanoactivator(R) in Germany for the Treatment of Brain Tumors at Frankfurt University Hospital

BERLIN & CARSON CITY, NEV.--()--MagForce AG Installs Fifth NanoActivator(R) in Germany for the Treatment of Brain Tumors at Frankfurt University Hospital

MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced the installation of the fifth NanoActivator(R). The device was installed at Frankfurt University Hospital to provide NanoTherm(TM) therapy for the treatment of brain cancers and the clinic will participate in MagForce's post marketing study. Since NanoTherm(TM) therapy has the European CE mark (in 27 EU countries), commercial patients can also be treated in Frankfurt. NanoActivator(R) devices are now available for treatment of patients with brain tumors at the University Medical Centers in Berlin, Münster, Kiel, Cologne, and Frankfurt.

About MagForce AG and MagForce USA, Inc.

MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm(TM) therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.

NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm(TM), NanoPlan(R), and NanoActivator(R) are trademarks of MagForce AG in selected countries.

For more information, please visit: www.magforce.com

Get to know our Technology: video (You Tube)

Stay informed and subscribe to our mailing list.

Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

Contacts

MC Services AG
Anne Hennecke
T +49 211 529252-22
F +49 211 529252-29
Email: anne.hennecke@mc-services.eu

Contacts

MC Services AG
Anne Hennecke
T +49 211 529252-22
F +49 211 529252-29
Email: anne.hennecke@mc-services.eu